R&D Regulatory setback or scientific signal? The case for human-... Exploring a systemic challenge in translating biological promise into reliable human efficacy and safety.
R&D From data to impact: How real-world evidence will transform ... Real-world evidence (RWE) has moved from the periphery to the centre of how healthcare decisions are made.
R&D The irony of data in precision medicine: Igniting progress w... As I regularly engage with pharma executives and biotech founders, a common theme inevitably arises: why is precision medicine taking so long to become a reality, and is technology to blame
Digital Tech & Trials: Can AI save us from drowning in data? Data – it’s everywhere! Especially in clinical trials, where an average trial of about 2,000 patients can expect to produce 3,000,000 points of data.
Patients The power of patient insights in shaping successful drug dev... The pharmaceutical industry is undergoing a major transformation, placing patients at the forefront of drug development like never before.
News Roche places a $1bn bet on C4T degrader-antibody conjugates Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
